Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses.
Malignant peripheral nerve sheath tumour
Neurofibromatosis type 1
Perineurinomas
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
11
05
2020
accepted:
25
05
2020
pubmed:
9
6
2020
medline:
22
6
2021
entrez:
8
6
2020
Statut:
ppublish
Résumé
Peripheral nerve sheath tumours in children are a rare and heterogeneous group, consisting mostly of benign tumours as well as malignant neoplasms. Especially in the paediatric population, diagnostics and indication for therapy pose relevant challenges for neurosurgeons and paediatric neurologists alike. Most paediatric cases that need surgical intervention are associated to neurofibromatosis type 1 (NF1). We retrospectively reviewed all paediatric cases treated at the Department of Neurosurgery in Tübingen between 2006 and 2017 for peripheral nerve sheath tumours. We analysed clinical signs, symptoms, histology, association to an underlying phacomatosis and sensory/motor function. Of the 82 identified patients, the majority had NF1 (76.8%). Nine children bore a sporadic tumour without underlying phacomatosis (11%), 8 had NF2 (9.8%) and 2 schwannomatosis (2.4%), A total of 168 surgical interventions were performed, and 206 tumours were removed. Indication for surgery was in most instances significant tumour growth (45.2%) followed by pain (33.9%). New deficits led to surgery in 12.5% of interventions; malignancy was suspected in 8.3%. Histopathology revealed mostly neurofibromas (82.5%), divided into cutaneous neurofibromas (10.7%), infiltrating plexiform neurofibromas (25.7%) and peripheral nerve-born neurofibromas (46.1%). 12.1% of tumours were schwannomas, 2.9% MPNST, 1.5% ganglioneuroma (n = 3) and 1 hybrid-neurofibroma and perineurinoma each. Leading symptoms, such as pain and motor and sensory deficits, improved after 125/166 interventions (74.4%), remained unchanged following 39 interventions (23.2%) and worsened in 4 occasions (2.4%). Surgery is safe and effective for (neurofibromatosis associated) peripheral nerve sheath tumours in the paediatric population; however, management needs a multidisciplinary setting. We propose early surgical resection in paediatric patients with peripheral nerve sheath tumours with significant growth, or pain, or motor deficit, or suspected malignancy.
Identifiants
pubmed: 32506255
doi: 10.1007/s00381-020-04703-6
pii: 10.1007/s00381-020-04703-6
pmc: PMC8272701
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2433-2442Commentaires et corrections
Type : ErratumIn
Références
Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, Aszmann O, Hojreh A, Peyrl A, Amann G, Benkoe TM, Wadsak W, Kasprian G, Staudenherz A, Hacker M, Traub-Weidinger T (2018) Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [(18) F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer 65. https://doi.org/10.1002/pbc.26733
Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P, Network NFF (2020) Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis 15:37. https://doi.org/10.1186/s13023-020-1310-3
doi: 10.1186/s13023-020-1310-3
pubmed: 32014052
pmcid: 6998847
Blakeley JO, Plotkin SR (2016) Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 18:624–638. https://doi.org/10.1093/neuonc/nov200
doi: 10.1093/neuonc/nov200
pubmed: 26851632
pmcid: 4827037
Campian J, Gutmann DH (2017) CNS tumors in neurofibromatosis. J Clin Oncol 35:2378–2385. https://doi.org/10.1200/JCO.2016.71.7199
doi: 10.1200/JCO.2016.71.7199
pubmed: 28640700
pmcid: 5516481
Carroll SL (2016) The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics. Am J Pathol 186:464–477. https://doi.org/10.1016/j.ajpath.2015.10.023
doi: 10.1016/j.ajpath.2015.10.023
pubmed: 26740486
pmcid: 4816695
Carvi y Nievas MN, Archavlis E, Unkel B (2010) Delayed outcome from surgically treated patients with benign nerve associated tumors of the extremities larger than 5 cm. Neurol Res 32:563–571. https://doi.org/10.1179/016164109X12581096870113
doi: 10.1179/016164109X12581096870113
pubmed: 20350365
Chick G, Alnot JY, Silbermann-Hoffman O (2000) Benign solitary tumors of the peripheral nerves. Rev Chir Orthop Reparatrice Appar Mot 86:825–834
pubmed: 11148420
Chick G, Victor J, Hollevoet N (2017) Six cases of sporadic schwannomatosis: topographic distribution and outcomes of peripheral nerve tumors. Hand Surg Rehabil 36:378–383. https://doi.org/10.1016/j.hansur.2017.07.001
doi: 10.1016/j.hansur.2017.07.001
pubmed: 28781128
Chick G, Victor J, Poujade T, Hollevoet N (2018) Sporadic schwannomatosis: a systematic review following the 2005 consensus statement. J Neurol Surg A Cent Eur Neurosurg 79:408–415. https://doi.org/10.1055/s-0038-1655548
doi: 10.1055/s-0038-1655548
pubmed: 29902824
Dunning-Davies BM, Parker AP (2016) Annual review of children with neurofibromatosis type 1. Arch Dis Child Educ Pract Ed 101:102–111. https://doi.org/10.1136/archdischild-2014-308084
doi: 10.1136/archdischild-2014-308084
pubmed: 26486853
Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, Maki RG (2014) Malignant peripheral nerve sheath tumors. Oncologist 19:193–201. https://doi.org/10.1634/theoncologist.2013-0328
doi: 10.1634/theoncologist.2013-0328
pubmed: 24470531
pmcid: 3926794
Fayad LM, Wang X, Blakeley JO, Durand DJ, Jacobs MA, Demehri S, Subhawong TK, Soldatos T, Barker PB (2014) Characterization of peripheral nerve sheath tumors with 3T proton MR spectroscopy. AJNR Am J Neuroradiol 35:1035–1041. https://doi.org/10.3174/ajnr.A3778
doi: 10.3174/ajnr.A3778
pubmed: 24287094
pmcid: 4086645
Garcia-Romero MT, Parkin P, Lara-Corrales I (2016) Mosaic neurofibromatosis type 1: a systematic review. Pediatr Dermatol 33:9–17. https://doi.org/10.1111/pde.12673
doi: 10.1111/pde.12673
pubmed: 26338194
Grill J, Dhermain F, Habrand JL (2009) Risks of radiation therapy in patients with neurofibromatosis. Int J Radiat Oncol Biol Phys 75:632. https://doi.org/10.1016/j.ijrobp.2009.03.076
doi: 10.1016/j.ijrobp.2009.03.076
pubmed: 19735889
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382:1430–1442. https://doi.org/10.1056/NEJMoa1912735
doi: 10.1056/NEJMoa1912735
pubmed: 32187457
pmcid: 7305659
Guedes F, Brown RS, Torrao-Junior FJL, Barbosa DAN, Ravanini GAG, Amorim RMP (2019) Pediatric peripheral nerve tumors: clinical and surgical aspects. Childs Nerv Syst 35:2289–2297. https://doi.org/10.1007/s00381-019-04306-w
doi: 10.1007/s00381-019-04306-w
pubmed: 31346736
Harder A, Wesemann M, Hagel C, Schittenhelm J, Fischer S, Tatagiba M, Nagel C, Jeibmann A, Bohring A, Mautner VF, Paulus W (2012) Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 36:702–709. https://doi.org/10.1097/PAS.0b013e31824d3155
doi: 10.1097/PAS.0b013e31824d3155
pubmed: 22446939
Karajannis MA, Ferner RE (2015) Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr 27:26–33. https://doi.org/10.1097/MOP.0000000000000169
doi: 10.1097/MOP.0000000000000169
pubmed: 25490687
pmcid: 4374132
Kehoe NJ, Reid RP, Semple JC (1995) Solitary benign peripheral-nerve tumours. Review of 32 years’ experience. J Bone Joint Surg Br 77:497–500
doi: 10.1302/0301-620X.77B3.7744945
Kiuru M, Busam KJ (2017) The NF1 gene in tumor syndromes and melanoma. Lab Invest 97:146–157. https://doi.org/10.1038/labinvest.2016.142
doi: 10.1038/labinvest.2016.142
pubmed: 28067895
pmcid: 5413358
Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM (1993) Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92–96. https://doi.org/10.1227/00006123-199307000-00014
doi: 10.1227/00006123-199307000-00014
pubmed: 8355853
Mehta GU, Huynh H, Lekovic GP (2019) Peripheral nerve sheath tumors in neurofibromatosis type 2: surgical and histopathologic features. Clin Neurol Neurosurg 190:105649. https://doi.org/10.1016/j.clineuro.2019.105649
doi: 10.1016/j.clineuro.2019.105649
pubmed: 31881415
Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A (2017) Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67:1–10. https://doi.org/10.1016/j.humpath.2017.05.010
doi: 10.1016/j.humpath.2017.05.010
pubmed: 28551330
pmcid: 5628119
Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M (2013) Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet A 161A:405–416. https://doi.org/10.1002/ajmg.a.35760
doi: 10.1002/ajmg.a.35760
pubmed: 23401320
Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbe NL, Bakker A, Viskochil D, Widemann BC, Stewart DR (2017) Neurofibromatosis type 1-associated MPNST state of the science: outlining a research agenda for the future. J Natl Cancer Inst 109. https://doi.org/10.1093/jnci/djx124
Rodriguez FJ, Folpe AL, Giannini C, Perry A (2012) Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 123:295–319. https://doi.org/10.1007/s00401-012-0954-z
doi: 10.1007/s00401-012-0954-z
pubmed: 22327363
pmcid: 3629555
Rosenbaum T, Wimmer K (2014) Neurofibromatosis type 1 (NF1) and associated tumors. Klin Padiatr 226:309–315. https://doi.org/10.1055/s-0034-1382021
doi: 10.1055/s-0034-1382021
pubmed: 25062113
Salamon J, Mautner VF, Adam G, Derlin T (2015) Multimodal imaging in neurofibromatosis type 1-associated nerve sheath tumors. Rofo 187:1084–1092. https://doi.org/10.1055/s-0035-1553505
doi: 10.1055/s-0035-1553505
pubmed: 26333104
Thomas AK, Egelhoff JC, Curran JG, Thomas B (2016) Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis. Pediatr Radiol 46:430–435. https://doi.org/10.1007/s00247-015-3482-x
doi: 10.1007/s00247-015-3482-x
pubmed: 26546566
Thway K, Fisher C (2014) Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol 18:109–116. https://doi.org/10.1016/j.anndiagpath.2013.10.007
doi: 10.1016/j.anndiagpath.2013.10.007
pubmed: 24418643
Tovmassian D, Abdul Razak M, London K (2016) The role of [(18)F]FDG-PET/CT in predicting malignant transformation of plexiform neurofibromas in neurofibromatosis-1. Int J Surg Oncol 2016:6162182–6162187. https://doi.org/10.1155/2016/6162182
doi: 10.1155/2016/6162182
pubmed: 28058117
pmcid: 5183794
Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B, Collaboration REI (2016) Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology 87:S4–S12. https://doi.org/10.1212/WNL.0000000000002927
doi: 10.1212/WNL.0000000000002927